FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and medicine. Presented is a complex of a type A toxin Clostridium botulinum, containing components HA70, HA17, HA33, NTNH, and BoNT/A1. Presented is a nucleic acid encoding the type A toxin Clostridium botulinum and a pharmaceutical composition for treating or preventing a disease caused by synaptic transmission or release of acetylcholine and for aesthetic medicine, containing the complex of the type A toxin Clostridium botulinum. Presented is a liquid agent for treating or preventing a disease caused by synaptic transmission or release of acetylcholine and for aesthetic medicine, containing the complex of the type A toxin Clostridium botulinum. Presented is an aesthetic medicine method and a method for treating or preventing a disease caused by synaptic transmission or release of acetylcholine in a subject in need thereof; an application of the complex of the type A toxin Clostridium botulinum, a pharmaceutical composition or a liquid agent when manufacturing a medicinal product, and an application of the complex of the type A toxin Clostridium botulinum, a pharmaceutical composition, or a liquid agent when manufacturing a product for aesthetic medicine.
EFFECT: compared to previously applied complexes of botulinum toxin, the botulinum toxin complex according to the present invention has a lower molecular weight, is safer, and has a significant therapeutic effect.
17 cl, 4 dwg, 18 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2766348C1 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| COMPOSITIONS OF IMMUNOGENIC/THERAPEUTIC GLYCOCONJUGATES AND USE THEREOF | 2015 |
|
RU2720295C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS WITH PROTECTIVE PROPERTIES AGAINST INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2768044C1 |
| METHODS AND COMPOSITIONS FOR INDUCTION OF IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE | 2018 |
|
RU2781057C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| COMPOSITIONS RELATED TO MUTANT TOXIN CLOSTRIDIUM DIFFICILE AND THEIR APPLICATION METHODS | 2017 |
|
RU2773880C1 |
